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A bstract
The angiotensin converting  enzym e (A C E) is  a  
strong candidate gene for m yocardial in farction  
(M I). Insertion-deletion d im orphism  in  intron 16 of 
th is gene has been inconclusively found to  be  
associated w ith  it. Several new  polym orphism s in  
the A C E  gene have been identified and am ong  
these, a dim orphism  in exon 17, ACE  G2350A, has  
a sign ificant effect on  p lasm a A C E concentra -
tions. To assess the value of genotyping the ACE  
G2350A dim orphism  in a genetically hom ogeneous  
population, we carried out a case-control study of 
d im orphism  G 2350A  for a putative association  
w ith  M I am ong Pakistani nationals. W e inves-
tigated a sam ple population  of 370 Pakistanis, 
com prising  163 contro ls, and 207 patients w ith  
clin ical d iagnosis of acute M I (A M I). A C E  G 2350A  
alleles w ere visualized by assays based on poly -
m erase chain reaction and restriction endonu -
clease analysis. Frequencies of G  alleles were 0.68  
am ong controls and 0.72 am ong AMI patients. The  
A C E  G 2350A  d im orphism  show ed no sign ificant 
association w ith  M I (χ 2 = 0.90, 2  d f, P = 0.64), 
p lasm a levels o f hom ocysteine (P = 0.52) or w ith  
serum  levels of folate (P = 0.299). The results indi-
cate that A C E  G 2350A  polym orphism  is not as-
sociated w ith  risk of m yocardial infarction in  the  
Pakistani population investigated here. 
Keywords: angiotensin converting enzyme; folic acid; 
genetics; homocysteine; myocardial infarction; Pakistani 
population
In troduction
Angiotensin converting enzyme (ACE) is a dipeptidyl 
carboxypeptidase I, (EC. 3.4.15.1) that activates angi-
otensin I through cleavage of the carboxyterminal 
dipeptide into the potent vasoconstrictor angiotensin 
II and inactivates the vasodilator peptide bradykinin 
(Erdös and Skidgel, 1987). Both are mediators of 
vascular tone and smooth muscle cell proliferation 
(Ehlers and Riordan, 1989). Experimental data sug-
gest that the presence of high levels of plasma ACE 
could result in the thickening of the vascular wall 
eventually leading to the development of vascular 
disease (Erdös and Skidgel, 1987; Ehlers and 
Riordan, 1989). 
  Circulating ACE levels show extensive inter- indi-
vidual variability and are highly genetically deter-
mined (Cambian et al., 1988; Alhenc-Gelas et al., 
1991). An insertion/deletion (I/D) dimorphism, due to 
the presence or absence of a 287 base pair (bp) 
alu-type sequence in intron 16 of the ACE gene, has 
been shown to cosegregate with serum and tissue 
ACE activities, and major locus inheritance explains 
best the findings that the D allele is associated with 
elevated ACE levels (Cambian et al., 1988; Rigat et 
al., 1990; Alhenc-Gelas et al., 1991). Thus, the ACE 
gene is viewed as a quantitative trait locus (QTL) that 
modulates circulating ACE levels, and the ACE I/D 
dimorphism is a marker that is thought to be in link-
age disequilibrium (LD) with functional variants locat-
ed in the ACE gene (Cambian et al., 1992; Tiret et 
al., 1992; Arca et al., 1998) that are implicated in 
CVDs. 
  Several studies on the association of ACE I/D 
polymorphism and the risk for myocardial infarction 
(MI) (Bohn et al., 1993; Cambien et al., 1994; Evans 
et al., 1994; Soubrier and Cambien, 1994; Cambian 
and Evans, 1995; Lindpainter et al., 1995; Villard and 
Soubrier, 1996; Ferrieres et al., 1999; O’ Mally et al., 
1999; Keavney et al., 2000), have generated incon-
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sistent information. This has stimulated a search for 
new polymorphisms in the ACE gene to identify better 
markers or actual functional variants. Accumulated 
evidence points to the existence of two QTLs at this 
chromosomal locus (McKenzie et al., 1995; Villard et 
al., 1996; Zhu et al., 2000; McKenzie et al., 2001). 
A genome-scan analysis by The Framingham Heart 
Study found strong evidence for a QTL on chro-
mosome 17, located close to the ACE gene and 
linked to blood pressure (Levy et al., 2000). Amongst 
the 13 polymorphisms of the ACE gene recently 
reported, a dimorphism in exon 17, ACE G2350A, has 
the most significant effect on plasma ACE concen-
trations (Zhu et al., 2001). After adjustment for the 
effect of ACE G2350A dimorphism, the I/D dimor-
phism was no longer associated with ACE, indicating 
that it is in LD with ACE G2350A and unlikely to be 
a functional mutation (Zhu et al., 2001).
  To assess the value of genotyping of ACE in Paki-
stani population, we carried out a case-control study 
of dimorphism G2350A for a putative association with 
MI and with plasma/serum levels of homocysteine and 
folate amongst Pakistani nationals. Our study is aimed 
at establishing whether the ACE G2350A dimorphism 
is a genetic marker and an independent risk factor 
for MI.
M ateria ls and M ethods
Study subjects
Two hundred and seven consecutive Pakistani pa-
tients with acute MI (AMI) (age, 30-70 years) admitted 
to the National Institute of Cardiovascular Diseases 
(NICVD), Karachi from January 2001 to June 2001, 
were selected for this study. They had confirmed 
diagnosis of AMI on the basis of clinical history, ECG 
and biochemical data.
  Similarly, 163 normal healthy subjects who had 
been matched for sex and to some extent for age 
and belonged to the same socio-economic class, 
were selected from the personnel of the Aga Khan 
University and Civil Hospital, Karachi for this study. 
Informed consent was obtained from the participants 
and the study was approved by the Ethical Committee 
of the Aga Khan University.
  A stringent criteria was used for the selection of 
normal healthy control subjects. In addition to being 
matched for age, sex and socioeconomic background, 
they had no evidence of CAD, diabetes mellitus, hy-
pertension, obesity and hypercholesterolemia. Those 
control subjects who were found to be pregnant, 
using antiepileptics, oral contraceptives, having mala-
bosorption syndrome, suffering from tuberculosis, ure-
mia, liver disease, or using B-complex vitamins during 
the last six months were excluded from this study.
D N A  analysis
Blood was collected in 10 m; Na-EDTA tubes and 
kept frozen at -20oC. DNA was extracted using stan-
dard protocols (Sambrook et al., 1989) and stored in 
10 mM Tris-HCl, 1 mM EDTA, pH 8.0.
  Codon 2350 ACE genotypes were first visualized 
by a method based on allele-specific oligonucleotides 
(McKenzie et al., 1995). It was then described as 
ACE-8 by Zhu et al. (2001), as a modification by 
introducing a mismatch guanine at the 3' end of the 
primer sequence, resulting in the amplification of a 
BstU1 restriction site. This more convenient method 
involves a set of primers designed to amplify a 
122-bp fragment encompassing the polymorphic re-
gion of ACE gene: 5'-CTGACGAATGTGATGGCCGC 3' 
(upstream) and 5'-TTGATGAGTTCCACGTATTTCG-3' 
(downstream). The PCR contained 100 to 200 ng 
DNA template, 125 µM dNTPs, 2.5 mM MgCl2, and 
0.3 mM of each primer and 1 U Taq polymerase, in 
a final volume of 10 µl. After initial denaturation at 
95oC for 5 min, PCR was carried out for 35 cycles, 
each one comprised of denaturation at 94oC for 30 
s, annealing at 58oC for 30 s, and extension at 72oC 
for 30 s, with a final extension time of 10 min at 72oC. 
PCR products (5 µl) were digested with 5 U of BstUI 
(Life Technologies) at 60oC for 2 h. Digested frag-
ments were separated by electrophoresis on 3% 
agarose gel and identified by ethidium bromide stain-
ing. Allele G2350 was visualized as a 122-bp frag-
ment and allele A2350 as 100-bp and 22-bp frag-
ments. 
D ata analysis
Statistical analyses were done with the help of an 
SPSSⓇ version 10.0 for WindowsⓇ software package 
(Gorinchem, The Netherlands). Distribution differences 
of G/A 2350 genotypes in the patients (AMI) as 
compared to distribution in the control group as well 
as Hardy-Weinberg proportions of allele distribution 
were assessed by chi-square analyses on 3×2 
tables. Means were compared using ANOVA. For all 
analyses, statistical significance was considered when 
significance level (P) values were lower than 0.05.
R esu lts
Demographic and clinical characteristics of patients 
have been listed in Table 1. The patient group 
comprised 51 females and 156 males, showing a 
female to male ration of 1:3. The mean age was 53±
9.6 years (range 30-70 years) in this group. Mean 
body mass index (BMI) was 24±5.6, while mean 
serum glucose concentration was 144±72 mg/dl. 
Mean cholesterol concentration was 185±45 mg/dl. 
43% of them were smokers, 31% were hypertensive, 
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57% were diabetic, while 19% were hypercholes-
terolemic. 26% of the patients had parental history of 
ischemic heart disease (IHD).
  Among the controls, the mean age was 49.3±9.6 
years (range 31-70 years). There were 123 males and 
40 females and the mean BMI for this group was 24
±5.6 which was quite close to the mean BMI of 
cases. 17% of the controls were smokers. 15% of the 
control subjects had parental history of IHD.
  Table 2 shows the data pertaining to both geno-
type and allele distributions in the two groups of sub-
jects. ACE genotypes did not occur in Hardy-Wein-
berg proportions in the normal control group (χ2 =
5.82, 2 degrees of freedom (df), P = 0.054) nor in AMI 
patients (χ2 = 0.90, 2 df, P = 0.64). 
  Differences in the distributions of the three genotypes 
according to clinical phenotype were not statistically 
significant (AMI vs Controls: χ2 = 3.1, 2 df, P = 0.217). 
  We also sought to explore association of 2350 G
＞A genotypes (GG, GA, AA) with several phenotypic 
T a b le  1 . Demographic and Clinical Characteristics of Subjects. (Mean±S.D)
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Controls (n = 163) Patients (n = 207)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Values Frequency (%) Values Frequency (%)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Age (Years) 49.3±9.6  53±9.6
Gender (Male) 123 (75.5) 156 (75.4)
      (Female)  40 (24.5)  51 (24.6)
Body mass index (kg/m2) 24.0±5.6 24.5±3.6
Glucose (mg/dl) 100±24 144±72*
Cholesterol (mg/dl) 168±34 185±45*
Smoking status (smokers)  17 43*
               (non-smokers)  83 57
Diet (vegetarian)   3  1
    (non-vegetarian)  97 99
Parental History of IHD (Yes)  15 26*
(No)  85 74
Hypertension (Yes)   0 31
          (No) 100 69
Diabetes (Yes)   0 56
       (No) 100 44
Homocysteine 17.8±7.7  17.8±8.2
Folate 5.33±3.44  3.33±3.81*
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*Indicates a significant difference from the control values (P ＜ 0.05).
Table 2 . Distribution of ACE G2350A genotypes and allele frequencies 
(±standard errors) in the AMI patients and normal healthy subjects.
Percentage values of genotypes are indicated in parentheses.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
AMI Normal healthy Genotype (n = 207) subjects (n = 163)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
GG 110 (53) 85 (52)
GA  76 (37) 52 (32)
AA  21 (10) 26 (16)
p (G allele) 0.72±0.04 0.68±0.04
q (A allele) 0.28±0.04 0.32±0.04
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Tab le  3 . Means (±S.D.) of age, BMI, plasma homocysteine and serum
folate values according to ACE G2350A dimorphism in the overall
sample population of this study.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
GG GA AAVariable *P-value(n = 195) (n = 128) (n = 47)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Age (years) 50.1±9.4 50.7±8.9 51.5±8.9  0.609
BMI 24.3±4.4 24.5±4.3 23.6±3.9  0.471
Homocysteine 18.1±8.4 17.8±8.2 16.6±5.4  0.52 (µmol/l)
Folate (ng/ml) 3.93±3.6 3.84±3.1 4.71±3.3 0.2991
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*P-value compares the mean values of the three genotypes for each
variable by oneway ANOVA.
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variables including age, BMI, serum folate and plasma 
homocysteine. There was no significant difference 
between the age and BMI profiles of the three geno-
types (Table 3). The homocysteine and serum folate 
values were also not statistically different between 
genotypes (Table 3). 
D iscussion
Association (retrospective case-control) studies are 
influenced by the effects of selection bias, population 
stratification, confounding by other variables, and clini-
cal criteria used to define patient groups. Minimizing the 
influence of the first two variables can be achieved by 
the exploration of putative associations in various ethnic 
groups that may be more genetically homogenous.
  Pakistani people belong to an ethnic group which 
is relatively homogeneous and has the high rates of 
coronary artery disease CAD (McKeigue et al., 1988). 
Moreover, the relative risk of CAD in South Asian men 
is the highest at early ages (Balerajan, 1991; Mc-
Keigue, 1992). This points to an increased genetic 
predisposition of this population to the development 
of CAD.
  “Control” individuals that were included in this 
investigation constituted a “comparison” rather than 
a “control” group. They were indeed free of disease, 
sex-matched with the patients, and had similar socio- 
economic background to that of the patients. As these 
control individuals had no evidence of MI, they repre-
sented a valid comparison group for these association 
studies, though it could not be predicted whether 
some of them would develop MI in future.
  Several studies have suggested that the D allele 
of ACE insertion/deletion (I/D) dimorphism confers 
increased risk for CVD (Cambien et al., 1992; 1994; 
Villard and Soubrier, 1996). At the same time, consi-
derable negative evidence exists on this question. An 
analysis of 11,000 cases and controls showed no 
relationship between MI and the I/D polymorphism 
(Evan et al., 1994). The I/D marker was likewise not 
associated with MI in Italian and French sample 
populations (Arca et al., 1998; Ferrieres et al., 1999). 
O'Malley et al. (1999) summarized the association 
between the I/D polymorphism and CVD risk, group-
ing studies by geographical region and disease 
prevalence. In this analysis the ACE I/D polymor-
phism did not appear to be a clinically useful indicator 
of risk for MI. Zhu et al. (2001) reported 13 polymor-
phisms in the ACE gene using linkage and associ-
ation studies. The polymorphism in exon 17, ACE 
G2350A had the most significant effect on plasma 
ACE concentration, accounting for 19% of the total 
variance in ACE plasma levels. After adjustment for 
the effect of ACE G2350A dimorphism, the I/D poly-
morphism was no longer associated with plasma ACE 
concentration, indicating that it is in LD with ACE 
G2350A and unlikely to be a functional mutation. 
Besides the effect on plasma ACE concentration, Zhu 
et al. (2001) reported that this dimorphism was signif-
icantly associated with SBP with an average increase 
of 3.2 mmHg with each copy of the G allele. These 
observations were suggestive of a possible role of 
ACE G2350A polymorphism in MI.
  We report the allele frequency of the ACE G2350A 
polymorphism in the Pakistani population to be 0.68±
0.04 and 0.32±0.04 for the G2350 and A2350 alleles 
respectively. In the present study, G2350A genotype 
distributions were not in Hardy-Weinberg proportions 
in the control group nor in the MI patient group. This 
may be a direct effect of consanguinity in this 
population.
  Our data on the Pakistani population did not show 
any significant association between G2350A polymor-
phism and MI. A recent study from our laboratory, 
reported a significant association between G2350A 
polymorphism and essential hypertension in Emirati 
population (Mahmood et al., 2003), indicating that this 
polymorphism may be the functional mutation of the 
ACE gene. However, no association of G2350A poly-
morphism was found with MI in Emirati population. 
Hyperhomocysteinemia has been an established risk 
factor MI. A recent report by Westphal et al. indicated 
that ACE inhibitors increase the plasma levels of 
homocysteine in hypertensive patients, thereby com-
promising to some extent the cardio-protective func-
tion usually associated with them (2003). This was 
also suggestive of a possible interaction between 
ACE gene expression and plasma level of homocy-
steine. Whether a polymorphic change in the ACE 
gene could have any influence on plasma homo-
cysteine level is unknown, therefore, we investigated 
whether there is any association between plasma 
levels of homocysteine and ACE G2350A polymor-
phism. Although we found decreased levels of plasma 
homocysteine in AA genotype (Table 3), the value 
was not significantly different from the values in GG 
and GA genotypes. This is suggestive of no associ-
ation between any of the three genotypes and plasma 
levels of homocysteine. Similarly, no association was 
observed between any of these three genotypes and 
serum folate levels.
  In summary, our data support that the G2350A 
dimorphism is neither associated with MI nor with 
plasma homocysteine or folate in the Pakistani popu-
lation. Given the complex nature of genetic suscep-
tibility for chronic degenerative diseases, further stud-
ies need to be conducted in individual ethnic groups 
to verify the disease relevance of this polymorphism.
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